Expertos Invitados





ABUSO DE SUSTANCIAS Y TRATAMIENTO ANTIPSICOTICO

(especial para SIIC © Derechos reservados)
Características especiales del uso de los antipsicóticos, en adictos a sustancias, que presentan con mayor frecuencia efectos adversos, tales como síntomas extrapiramidales y menor adherencia a los tratamientos.
Autor:
Enriqueta Ochoa mangado
Columnista Experto de SIIC
Artículos publicados por Enriqueta Ochoa mangado
Recepción del artículo
9 de Octubre, 2002 		Primera edición
18 de Noviembre, 2002 		Segunda edición, ampliada y corregida
7 de Junio, 2021

ABUSO DE SUSTANCIAS Y TRATAMIENTO ANTIPSICOTICO

Resumen
Se realiza una revisión en la bibliografía de los últimos 10 años (Medline, IME, HealthSTAR, Cinahl) sobre la utilización de los antipsicóticos en dependientes de sustancias. El uso de estos fármacos es frecuente en esta población dada la elevada prevalencia de drogodependientes con patología psicótica, así como su utilización en el tratamiento de situaciones derivadas del consumo de algunas sustancias y en los trastornos de conducta secundarios a trastorno mental orgánico o de personalidad. Se revisan las características especiales del uso de antipsicóticos en esta población adicta a sustancias, que presentan con mayor frecuencia efectos adversos, como síntomas extrapiramidales y menor adherencia a los tratamientos.

Palabras clave
Antipsicóticos, patología dual, abuso de sustancias, efectos secundarios


Artículo completo
(castellano)
Extensión:  +/-12.27 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes
Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Salud Mental
Relacionadas: Farmacología, Geriatría, Medicina Interna



Comprar este artículo
Extensión: 12.27 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Bibliografía del artículo
  1. Stowell RJ. Dual diagnosis issues. Psychiatr Ann 1991; 21: 98-104.
  2. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990; 264: 2511-8.
  3. Weller MP, Ang PC, Latimer-Sayer DT, Zachary A. Drug abuse and mental illness. Lancet 1988; 1: 997.
  4. Brady KT, Anton R, Ballanger JC Lydiard RB, Adinoff B, Selander J. Cocaine abuse among schizophrenic patients. Am J Psychiatry 1990; 147: 1164-7.
  5. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. Am J Psychiatry 1991; 148: 224-30.
  6. Shaner A, Khalsa ME, Roberts L, Wilkins J, Anglin D, Hsieh S. Unrecognized cocaine use among schizophrenic patients. Am J Psychiatry 1993; 150: 758-62.
  7. Chouljian TL, Shumway M, Balancio E, Valdes E, Surber R. Substance use among schizophrenic outpatients: prevalence, course, and relation to funtional status. Annals Clinical Psychiatry 1995; 7: 19-24.
  8. Brunette MF, Mueser KT, Xie H, Drake RE. Relationship between symptoms of schizophrenia and substance abuse. J Nerv Ment Dis 1997; 185: 13-20.
  9. Buckley PF. Substance abuse in schizophrenia: a review. J Clin Psychiatry 1998; 59 Suppl 3: 26-30.
  10. Arias F, Padin JJ, Fernandez-Gonzalez MA. Consumo y dependencia de drogas en la esquizofrenia. Actas Luso Esp Neurol Psiquiatr 1997; 25(6): 379-89.
  11. Menezes PR, Johnson S, Thornicroft G, Marshall J, Prosser D, y col. Drug and alcohol problems among individuals with severe mental ilnesses in south London. Br J Psychiatry 1996; 168: 612-9.
  12. Allebeck P, Adamsson C, Engstrom A. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Act Psychiatr Scand 1993; 88: 21-4.
  13. Ochoa E, Vicente N. Esquizofrenia en una población de adictos a opiáceos en tratamiento con naltrexona. Psiquiatría Biológica 1996; 3: 85-9.
  14. Limbeek JV, Wouters L, Kaplan CD, Geerlings PJ, Alem VV. Prevalence of psychopathology in drug-addicted Dutch. J Subst Abuse Treat 1992; 9: 43-52.
  15. Pérez de los Cobos J, Casas M. Opiáceos y Esquizofrenia. En: Trastornos psíquicos en las toxicomanías. En: M Casas (ed). Ediciones en Neurociencias, Barcelona, 1992; 91-104.
  16. Brady KT, Lydiard RB, Malcolm R, Ballenger JC. Cocaine-induced psychosis. J Clin Psychiatry 1991; 52: 509-12.
  17. Tien AY, Anthony JC. Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. J Nerv Ment Dis 1990; 178: 473-80.
  18. Sterling RC, Gottheil E, Weinstein SP, Shannon DM. Psychiatric symptomatology in crack cocaine abusers. J Ner Ment Dis 1994; 182: 564-9.
  19. Rounsaville BJ, Anton SF, Carroll K, Budde D, Prusoff BA, Gawin F. Psychiatric diagnoses of treatment-seeking cocaine abusers. Arch Gen Psychiatry 1991; 48: 43-51.
  20. Smith J, Hucker S. Schizophrenia and substance abuse. Br J Psychiatry 1994; 165: 13-21.
  21. LeDuc PA, Mittleman G. Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. Psychopharmacol 1995; 121: 407-27.
  22. Westermeyer J. Schizophrenia and substance abuse. En: Tasman A, Riba MB (eds). Review of psychiatry. Vol. 11. Washington: American Psychiatric Press; 1992.
  23. Zisook S, Heaton R, Moranville J, Kuck J, Jernigan T, Braff D. Past substance abuse and clinical course of schizophrenia. Am J Psychiatry 1992; 149: 552-3.
  24. Peralta V, Cuesta MJ. Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand 1992; 85: 127-130.
  25. Serper MR, Alpert M, Trujillo M. Recent cocaine use decreases negative signs in acute schizophrenia: a case study over two consecutive admissions. Biol Psychiatry 1996; 39(9): 816-8.
  26. Nuñez LA. Consumo de cannabis en sujetos esquizofrénicos. Adicciones 1998; 10: 239-45.
  27. Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia: a prospective community study. J Nerv Ment Dis 1989; 177: 408-14.
  28. Newman R, Miller N. Substance abuse and psychosis. Current Op Psychiatr 1992; 5: 25-8.
  29. Cornelius JR, Salloum IM, Mezzich J, Cornelius MD, Fabrega H, Ehler JG, y col. Disproportionate suicidality in patients with comorbid major depression and alcoholism. Am J Psychiatry 1995; 152: 358-64.
  30. Mueser KT, Drake RE, Miles KM. The course and treatment of substance use disorder in persons with severe mental illness. NIDA Res Monogr 1997; 172: 86-109.
  31. Neeleman J, Farrell M. Suicide and substance misuse. Br J Psychiatry 1997; 171: 303-4.
  32. Soni SD, Brownlee M. Alcohol abuse in chronic schizophrenics: implications for management in the community. Acta Psychiatr Scand 1991; 84: 272-6.
  33. Ayuso-Gutierrez JL, del Rio J. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997; 28: 199-206.
  34. Seibyl JP, Satel SL, Anthony D, Southwick SM, Krystal JH, Charney DS. Effects of cocaine on hospital course in schizophrenia. J Nerv Ment Dis 1993; 181: 31-7.
  35. Gerding LB, Labbate LA, Measom MO, Santos AB, Arana GW. Alcohol dependence and hospitalization in schizophrenia. Schizophr Res 1999; 38(1): 71-5.
  36. Arndt S, Tyrrell G, Flaum M, Andreasen NC. Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment. Psychol Med 1992; 22: 379-88.
  37. Hall W, Farrell M. Comorbidity of mental disorders with substance misure. Br J Psychiatry 1997; 171: 4-5.
  38. Bartels SJ, Teague GB, Drake RE, Clark RE, Bush PW, Noordsy DL. Substance abuse in schizophrenia: Service utilization and costs. J Nerv Ment Dis 1993; 181: 227-32.
  39. Martínez MJ, Varo JR, Aguinaga M, Calcedo A. Consumo de cannabis y alcohol como factores pronósticos en la evolución a corto plazo de la esquizofrenia. Actas Luso Esp Neurol Psiquiatr 1995; 23: 189-92.
  40. Drake RE, Wallach MA. Moderate drinking among people wiyh severe mental illness. Hospital Community Psychiatry 1993; 44: 780-2.
  41. Pérez de los Cobos J, Casas M. Toxicomanías y trastornos psíquicos concomitantes: El consumo de drogas en la esquizofrenia. En Nuevas Perspectivas en Psiquiatría Biológica. Ed. Cervera S. y Martínez-Villa E, Eurograf, Pamplona, 1995; 677-93.
  42. Schumauss C, Yassouridis A, Emrick HM. Antipsychotic effect of buprenorphine in schizophrenia. Am J Psychiatry 1987; 144: 1340-42.
  43. Brizer DA, Hartman N, Sweeney J, Millman RB. Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia. Am J Psychiatry 1985; 142: 1106-7.
  44. Johnson S. Dual diagnosis of severe mental illness and substance misuse: a case for specialist services. Br J Psychiatry 1997; 171: 205-8.
  45. Nigam R, Schottenfeld R, Kosten TR. Treatment of dual diagnosis patients: a relapse prevention group approach. J Subst Abuse Treat 1992; 9: 305-9.
  46. Crawford V. Comorbidity of substance misure and psychiatric disorders. Current Opinion Psychiatry 1996; 9: 231-4.
  47. American Psychiatric Association. Directrices para la práctica clínica en el tratamiento de pacientes con trastornos por consumo de sustancias. Barcelona: Edika Med, 1997.
  48. Hellerstein DJ, Rosenthal RN, Miner CR. A prospective study of integrated outpatient treatment for substance-abusing schizophrenic patients. Am J Addictions 1995; 4: 33-42.
  49. Mowbray CT, Solomon M, Ribisl KM, Ebejer MA, Deiz N, Brown W, et al. Treatment for mental illness and substance abuse in a public psychiatric hospital. J Subst Abuse Treat 1995; 12: 129-39.
  50. Miller L, Guttman. The integration of pharmacological therapy for comorbid psychiatric and addictive disorders. J Psychoactive Drugs 1997; 29: 249-54.
  51. Satel SL, Southwick SM, Gawin FH. Clinical features of cocaine-induced paranoia. Am J Psychiatry 1991; 148: 495-8.
  52. D¨Mello DA, Boltz MK, Msibi B. Relationship between concurrent substance abuse in psychiatric patients and neuroleptic dosage. Am J Drug Alcohol Abuse 1995; 21: 257-65.
  53. Wilkins JN. Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Schizophr Bull 1997; 23(2): 215-28.
  54. Bailey L, Maxwell S, Brandabur MM. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1027 patients. Psychopharmacol Bull 1997; 33: 177-81.
  55. Satel SL, Swann AC. Extrapyramidal symptoms and cocaine abuse (letter). Am J Psychiatry 1993; 150: 347.
  56. Sevy S, Kay SR, Opler LA, Van Praag HM. Significance of cocaine history in schizophrenia. J Nerv Ment Dis 1990; 178: 642-8.
  57. Van Harten PN, Van Trier JC, Horwitz EH, Matroos GE, Hoek HW. Cocaine as a risk factor for neuroleptic-induced acute dystonia. J Clin Psychiatry 1998; 59: 128-30.
  58. Kosten TA. Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats. Schrizophrenia Bull 1997; 23: 203-13.
  59. Kosten TA, Nestler FJ. Clozapine attenuates cocaine conditioned place preference. Life Science 1994, 55: 9-14.
  60. Meil WM, Schechter MD. Olanzapine attenuates the reinforcing effects of cocaine. Eur J Pharmacol 1997; 340: 17-26.
  61. Smelson DA, Roy A, Roy M. Risperidone disminishes cue-elicited craving in withdrawn cocaine-dependent patients. Can J Psychiatry 1997; 42: 984.
  62. Avila JJ, Alvarez A. Tratamiento de los trastronos comórbidos en pacientes dependientes de opiáceos. Monografías Psiquiatría 1999; 4: 41-8.
  63. Wines JD, Weiss RD. Opioid withdrawal during risperidone treatment. J Clin Psychopharmacol 1999; 19(3): 265-7.
  64. Marchesi GF, Santone G, Cotani P, Giordano A, Chelli F. Naltrexone in chronic negative schizophrenia. Clin. Neuropharm. 1992; 15 (suppl. 1): 56A-7A.
  65. Knudsen P, Vilmar T. Cannabis and neuroleptic agents in schizophrenia. Act Psychiatr Scand 1984; 69: 162-74.
  66. Tandon R, Dutchak D, Greden JF. Cholinergic syndrome following anticholinergic withdrawal in a schizophrenic patient abusing marijuana. Br J Psychiatry 1989; 154: 712-4.
  67. Duke PJ, Pantelis C, Barnes TRE. South Westminster Schizophrenia Survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. Br J Psychiatry 1994; 164: 630-6.
  68. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am J Psychiatry 1992; 149: 1189-94.
  69. Pantuck EJ, Pantuck CB, Anderson KE, y col. Cigarette smoking and chlorpromazine disposition and actions. Clin Pharmacol Ther 1982; 31: 533-8.
  70. Levin ED, Wilson W, Rose JE, McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacol. 1996; 15: 429-36.
  71. Lee C, Frangou S, Russell MAH, Gray JA. Effect of haloperidol on nicotine-induced enhancement of vigilance in human subjects. J Psychopharmacol 1997; 11: 253-7.
  72. McEvoy JP, Freudenreich O, Levin ED, Rose JE. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacol 1995; 119: 124-6.
  73. Griffith JM, O´Neill JE, Petty F, Garver D, Young D, Freedman R. Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biol Psychiatry 1998; 44: 98-106.
  74. McEvoy JP, Brown S. Smoking in first-episode patients with schizophrenia (letter). Am J Psychiatry 1999; 156: 1120-1.
  75. Dalack GW, Meador-Woodruff JH. Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schizophr Res 1996; 22: 133-41.
  76. George TP, Sermyak MJ, Ziedonis DM, Woods SW. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 1995; 56: 344-6.
  77. Siris SG. Substance abuse in schizoprenia. J Nerv Ment Dis 1992, 180: 595-6.
  78. Conley RR, Meltzer HY. Adverse events related to olanzapine. J Clin Psychiatry 2000; 61 Suppl 8: 26-30.
  79. Tandon R, Milner K, Jibson MD. Antipsychotics from theory to practice: integrating clinical and basic data. J Clin Psychiatry 1999; 60 Suppl 8: 21-8.
  80. Ganguli R. Weight gain associated with antipsychotic drugs. J Clin Psychiatry 1999; 60 Suppl 21: 20-4.
  81. Gupta S, Droney T, Al-Samarrai S, Keller P, Frank B. Olanzapine: weight gain and therapeutic efficacy [letter]. J Clin Psychopharmacol 1999; 19(3): 273-5.
  82. Conley RR. Risperidone side effects. J Clin Psychiatry 2000; 61 Suppl 8: 20-3. Discussion 24-5.
  83. Ho BC, Miller D, Nopoulos P, Andreasen NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999; 60(10): 658-63.
  84. DasGupta K, Young A. Clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry 1991; 52, 105-7.
  85. Aguirre C, García JC, Mendibil B. Síndrome neuroléptico maligno asociado a risperidona. Med Clin Barc 1998; 110(6): 239.
  86. Burkhard PR, Vingerhoets FJ, Alberque C, Landis T. Olanzapine-induced neuroleptic malignant syndrome [letter]. Arch Gen Psychiatry 1999; 56(1): 101-2.
  87. García MM, Cipres L, de Cendra E, Vilalta J. Sindrome neuroleptico maligno asociado a olanzapina. Med Clin Barc 1999; 113(6): 239.
  88. Levenson JL. Neuroleptic malignant syndrome after the initiation of olanzapine [letter]. J Clin Psychopharmacol 1999; 19(5): 477-8.
  89. Ahmed S, Chengappa KN, Naidu VR, Baker RW, Parepally H, Schooler NR. Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J Clin Psychiatry 1998; 59(9): 472-7.
  90. Campbell M. Risperidone-induced tardive dyskinesia in first-episode psychotic patients [letter]. J Clin Psychopharmacol 1999; 19(3): 276-7.
  91. Hong KS, Cheong SS, Woo JM, Kim E. Risperidone-induced tardive dyskinesia [letter]. Am J Psychiatry 1999; 156(8): 1290.
  92. Silberbauer C. Risperidone-induced tardive dyskinesia. Pharmacopsychiatry 1998; 31(2): 68-9.
  93. Kumar S, Malone DM. Risperidone implicated in the onset of tardive dyskinesia in a young woman. Postgrad Med J 2000; 76(895): 316-7.
  94. Carroll NB, Boehm KE, Strickland RT. Chorea and tardive dyskinesia in a patient taking risperidone [letter]. J Clin Psychiatry 1999; 60(7): 485-7.
  95. Ananth J, Kenan J. Tardive dyskinesia associated with olanzapine monotherapy [letter]. J Clin Psychiatry 1999; 60(12): 870.
  96. Dunayevich E, Strakowski SM. Olanzapine-induced tardive dystonia [letter]. Am J Psychiatry 1999; 156(10): 1662.
  97. Landry P, Cournoyer J. Acute dystonia with olanzapine [letter]. J Clin Psychiatry 1998; 59(7): 384.
  98. Herran A, Vazquez-Barquero JL. Tardive dyskinesia associated with olanzapine [letter]. Ann Intern Med 1999; 131(1): 72.
  99. Snoddgrass PL, Labbate LA. Tardive dyskinesia from risperidone and olanzapine in an alcoholic man. Can J Psychiatry 1999; 44(9): 921.
  100. Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 2000; 61 Suppl 4: 21-6.
  101. Jaffe ME, Simpson GM. Reduction of tardive dystonia with olanzapine [letter]. Am J Psychiatry 1999; 156(12): 2016.
  102. Almeida OP. Olanzapine for the treatment of tardive dyskinesia [letter]. J Clin Psychiatry 1998; 59(7): 380-1.
  103. Littrell KH, Johnson CG, Littrell S, Peabody CD. Marked reduction of tardive dyskinesia with olanzapine [letter]. Arch Gen Psychiatry 1998; 55(3): 279-80.
  104. Lykouras L, Malliori M, Christodoulou GN. Improvement of tardive dyskinesia following treatment with olanzapine. Eur Neuropsychopharmacol 1999; 9(4): 367-8.
  105. Soutullo CA, Keck PE Jr, McElroy SL. Olanzapine in the treatment of tardive dyskinesia: a report of two cases. J Clin Psychopharmacol 1999;19(1):100-1.
  106. Gotto J. Treatment of respiratory dyskinesia with olanzapine. Psychosomatics 1999; 40(3): 257-9.
  107. Geller WK, Zuiderwijk PB. Risperidone-induced hepatotoxicity [letter]. J Am Acad Child Adolesc Psychiatry 1998; 37(3): 246-7.
  108. Whitworth AB, Liensberger D, Fleischhacker WW. Transient increase of liver enzymes induced by risperidone: two case reports [letter]. J Clin Psychopharmacol 1999; 19(5): 475-6.
  109. Buckley P, Thompson P, Way L, Meltzer HY. Substance abuse among patients with treatment-resistant schizophrenia: Characteristics and implications for clozapine therapy. Am J Psychiatry 1994; 151: 385-9.
  110. Soler PA. Abuso y dependencia de antiparkinsonianos. En: Casas M, Gutierrez M, San L, eds. Adicciones a psicofármacos. Barcelona. Ediciones en Neurociencias, 1993.
  111. PSA-R. Trastornos por abuso de sustancias. Autoevaluación y actualización en psiquiatría. 1999.
  112. PSA-R. Esquizofrenia y otros trastornos psicóticos. Autoevaluación y actualización en psiquiatría. 1999.
  113. Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine (letter). Am J Psychiatry 1995; 152: 959.
  114. Conley RR, Kelly DL, Gale EA. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res 1998; 33: 95-101.
  115. Misra LK, Kofoed L, Oesterheld JR, Richards GA. Olanzapine treatment of methamphetamine psychosis. J Clin Psychopharmacol 2000; 20: 393-4.
  116. Jha A, Fourie H. Risperidone treatment of amphetamine psychosis [letter]. Br J Psychiatry 1999; 174: 366.
  117. Misra LK, Kofoed L, Fuller W. Treatment of inhalant abuse with risperidone [letter]. J Clin Psychiatry 1999; 60(9): 620.
  118. Berk M, Brook S, Trandafir AI. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int Clin Psychopharmacol 1999; 14(3):177-80.
  119. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35(1): 51-68.
  120. Tsuang JW, Eckman TE, Shaner A, Marder SR. Clozapine for substance-abusing schizophrenic patients (letter). Am J Psychiatry 1999; 156: 1119-20.
  121. Carrillo JA, Herraiz AG, Ramos SI, Benítez J. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol 1998; 18: 311-16.
  122. Bosch RF, Baumbach A, Bitzer M, Erley CM. Intoxication with olanzapine [letter]. Am J Psychiatry 2000; 157(2): 304-5.
  123. Gardner DM, Milliken J, Dursun SM. Olanzapine overdose [letter]. Am J Psychiatry 1999; 156(7): 1118-9.
  124. Meltzer HY. Outcome in schizophrenia: beyond symptom reduction. J Clin Psychiatry 1999; 60: (suppl3) 3-7.
  125. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25(2): 233-55.
  126. De Girolamo G, Reich JH. Epidemiología de los trastornos mentales y de los problemas psicosociales: trastornos de la personalidad. OMS. Meditor (eds), Madrid 1996.
  127. Cervera G, Bolinches F, Valderrama JC. Trastornos de personalidad y drogodependencias. Trastornos adictivos 1999; 1: 991-9.
  128. Ekleberry, S. Dual Diagnosis: Adiction and Axis II Personality Disorders. The Counselor, March/April: 1996; 7-13.
  129. Toner BB, Gillies LA, Prendergast P, Core FH, Browne C. Substance use disorders in a sample of canadian patients with chronic mental illness. Hosp Community Psychiatry 1992; 43: 251-4.
  130. Baxter L, Edell W, Gerner R, y col. Dexamethasone suppression test and axis I diagnoses of inpatients with DSM-III borderline personality disorder. J Clin Psychiatry 1984; 45: 150-3.
  131. Dulit RA, Fyer MR, Haas GL, Sullivan T, Frances AJ. Substance use in borderline personality disorder. Am J Psychiatry 1990; 147: 1002-7.
  132. Casas M. Trastornos de personalidad en pacientes adictos a opiáceos. En: Trastornos psíquicos en las toxicomanías. Neurociencias. Barcelona 1993: 305-12.
  133. Sánchez E, Tomás V, Climent A. Trastornos de personalidad en adictos a opiáceos. Adicciones 1999; 11: 221-7.
  134. Brooner RK, Herbst JH, Schmidt CW, Bigelow GE, Costa PT. Antisocial personality disorder among drug abusers. Relations to other personality diagnoses and the five-factor model of personality. J Nerv Ment Dis 1993; 181: 313-9.
  135. Khantzian EJ, Treece C. DSM-III psychiatric diagnosis of narcotic addicts. Recent findings. Arch Gen Psychiatry 1985; 42: 1067-71.
  136. San Narciso GI, Gutiérrez E, Saíz PA, González MP, Bascarrán MT, Bobes J. Evaluación de trastornos de personalidad en pacientes heroinómanos mediante el IPDE. Adicciones 2000; 12: 43-6.
  137. Carroll KM, Ball SA, Rounsaville BJ. A comparison of alternate systems for diagnosing antisocial personality disorder in cocaine abusers. J Nerv Ment Dis 1993; 181: 436-43.
  138. Weiss RD, Mirin SM, Griffin ML, Gunderson JG, Hufford C. Personality disorders in cocaine dependence. Comp. Psychiatry 1993; 34: 145-9.
  139. Koenigsberg HW, Kaplan RD, Gilmore MM, Cooper AM. The relationship between syndrome and personality disorder in DSM-III: Experience with 2.462 patients. Am J Psychiatry 1985; 142: 207-12.
  140. Nace EP, Davis CW, Gaspari JP. Axis II comorbidity in substance abusers. Am J Psychiatry 1991; 148: 118-20.
  141. Blow FC, Loveland CA, Booth BM, Falcon SP, Friedman MJ. Age-related psychiatric comorbidities and levels of functioning in alcoholic veterans seeking outpatient treatment. Hosp Community Psychiatry 1992; 43: 990-5.
  142. Brooner RK, King VL, Kidorf M, y col. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 1997; 54: 71-80.
  143. Bunt G, Galanter M, Lifshutz H, Castaneda R. Cocaine/"crack" dependence among psychiatric inpatients. Am J Psychiatry 1990; 147: 1542-6.
  144. Dinwiddle SH, Reich T, Cloninger CR. Psychiatric comorbidity and suicidality among intravenous drug users. J Clin Psychiatry 1992; 53: 364-9.
  145. Gill K, Nolimal D, Crowley TJ. Antisocial personality disorder, HIV risk behavior and retention in methadone maintenance therapy. Drug Alcohol Depend 1992; 30: 247-52.
  146. Compton WM, Cottler LB, Spitznagel EL, Ben Abdallah A, Gallagher T. Cocaine users with antisocial personality improve HIV risk behaviors as much as those without antisocial personality. Drug Alcohol Depend, 1998; 49: 239-47.
  147. Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999; 46(10): 1429-35.
  148. SEIT. Sistema Estatal de Información sobre Toxicomanias. Plan Nacional sobre Drogas 1995.
  149. Crone B. Gender differences in substance misure and psychiatric comorbidity. Current Opinion Psychiatry 1997; 10: 194-8.
  150. Weiss RD, Martinez-Raga J, Griffin ML, Greenfield SF, Hufford C. Gender differences in cocaine dependent patients: a 6 month follow-up study. Drug Alcohol Depend 1997; 44(1): 35-40.
  151. Anta GB, Orta JV, Portela MJ, DeHoz LD. The epidemiolgy of cocaine in Spain. Drug Alcohol Depend 1993; 34: 45-57.
  152. Gossop M, Griffiths P, Powis B, Strang J. Cocaine: patterns of use, route of administration and severity of dependence. Br J Psychiatry 1994; 164: 660-4.
  153. Schifano F. Cocaine misure and dependence. Current Opinion Psychiatry 1996; 9: 225-30.
  154. Spitz HI, Rosecan JS. Abuso de cocaína. Eds Neurociencias. Barcelona 1990.
  155. Asociación Psiquiátrica Americana. Manual Diagnóstico y Estadístico de los Trastornos Mentales. 4ª eds. Editorial Masson. Barcelona, España. 1995.
  156. Galindo A. Manejo del paciente con dependencia a la cocaína. Trastornos Adictivos 2000; 2: 122-32.
  157. Gawin FH, Kleber HD. Abstinence symptomatology and psychiatric diagnosis in chronic cocaine abusers. Arch Gen Psychiatric 1986; 43: 107-13.
  158. Satel SL, Price LH, Palumbo JM, McDougle CJ, Krystal JH, Gaxin F. Clinical phenomenology and neurobiology of cocaine dependence: a prospective inpatient study. Am J Psychiatry 1991; 148: 1712-6.
  159. Gawin FH. Neuroleptic reduction of cocaine-induced paranoia but not euphoria Psychopharmacology (Berl) 1986; 90: 142-3.
  160. San L, Arranz B, Ramírez N. Tratamiento psicofarmacológico de la dependencia de cocaína. Trastornos Adictivos 1999; 1: 34-47.
  161. Levin FR, Evans SM, Coomaraswammy S, Collins DE, Regent N, Kleber HD. Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study. Am J Drug Alcohol Abuse 1998; 24(3): 343-60.
  162. Dhopesh V, Macfadden A, Maany I, Gamble G. Absence of parkinsonism among patients in long-term neuroleptic therapy who abuse cocaine. Psychiatr Serv 1997; 48(1): 95-7.
  163. Fenton TW. AIDS related psychiatric disorder. Brit J Psychitr 1987; 151: 579-88.
  164. Ochoa E. Psicopatología en pacientes VIH+. Trastornos Adictivos 1999; 1: 100-9.
  165. Perry SW. Organic mental disorders caused by HIV: update on early diagnosis and treatment. Am J Psychiatry 1990; 147: 696-710.
  166. Treisman G, King J, Lyketsos C, Fishman M. Neuropsychiatry and HIV infection. Curren Opinion Psychiatry 1994; 7: 102-5.
  167. Lozano M, Padín JJ, Buzón L. Trastornos mentales en la infección por VIH-1. Rev Clin Española 1996; 11: 774-84.
  168. Pérez-Poza A, Pérez-Echeverría MJ, Pascual A, Civeira JM, Día JL. Aspectos psiquiátricos en pacientes con SIDA en el hospital general. Anales de Psiquiatria 1998; 14: 411-15.
  169. Andres Medina R. Epidemiología del VIH/SIDA en usuarios de drogas en España. Aspectos contextuales. Adicciones 1995; 7, 277-98.
  170. Vigilancia epidemiológica del SIDA/HIV, situación a nivel nacional y regional. Dirección General de Salud Pública. Informe trimestral nº3, 1998.
  171. Delegación del Gobierno para el Plan Nacional sobre Drogas. Carecterísticas de los centros con tratamiento de mantenimiento con metadona en España. Madrid 1999.
  172. García A, Ezquiaga E. Trastornos neuropsicológicos en toxicómanos. Actas Luso-Esp Neurol Psiquiatr 1988; 16: 425-33.
  173. Fals-Stewart W; Schafer J. The relationship between length of stay in drug-free therapeutic communities and neurocognitive functioning. J Clin Psychol 1992; 48: 539-43.
  174. Saunders PA, Copeland JRM, Dewey ME, y col. Heavy drinking as a risk factor for depression and dementia in elderly men. Findings from the Liverpool Longitudinal Community Study. Br J Psychiatry 1991; 159: 213-16.
  175. Parsons OA. Intellectual impairment in alcoholics: Persisten issues. Acta Med Scand 1987; 717 (suppl): 33-46.
  176. Mateu G, Cendros P, Martin-Santos R, Torrens M. Fármacos antirretrovirales: interacciones con agentes psicotrópicos y efectos secundarios neuropsiquiátricos. Psicofarmacología 2000; 4: 23-32.
  177. Fuerte A, Otero MJ. Interacciones de los fármacos antirretrovirales. Med Clin (Barc) 1999; 26: 94-102.
  178. Tseng AL, Foisy MM. Significant interaccions with new antiretrovirals and psychotropic drugs. Ann Pharmacother 1999; 44: 190-4.
  179. Hriso E, Kuhn T, Masdeu JC, Grundman M. Extrapyramidal symptoms due to dopamine-blocking abents in patient with AIDS encephalopaty. Am J Psychiatry 1991; 148: 1558-61.
  180. Lodge P, Tanner M, McKeogh MM. Risperidone in the management of agitation in HIV dementia [letter]. Palliat Med 1998; 12(3): 206-7.
  181. Maha A, Goetz K. Risperidone for the treatment of delusional disorder due to HIV disease [letter]. J Neuropsychiatry Clin Neurosci 1998; 10(1): 111.
  182. Singh AN, Golledge H, Catalan J. Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases. J Psychosom Res 1997; 42(5): 489-93.
  183. PSA-R. Delirium y demencia. Autoevaluación y actualización en psiquiatría. 1999.
  184. Breitbar W, Marotta R, Platt MM y col. A doble-blind trial of haloperidol, chlorpromazine and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153: 231-37.
  185. Sipahimalani A, Masand PS. Olanzapine in the treatment of delirium. Psychosomatics 1998; 39(5): 422-30.
  186. Anand HS. Olanzapine in an intensive care unit [letter]. Can J Psychiatry 1999; 44(4): 397.
  187. Passik SD, Cooper M. Complicated delirium in a cancer patient successfully treated with olanzapine. J Pain Symptom Manage 1999;17(3):219-23.
  188. Salzmar C, Vaccaro B, Lieff J, Weiner A. Clozapine in older patients with psichoses and behavioral disturbances. Am J Geriatr Psychiatry 1995; 3: 26-33.
  189. Barcia D, Giles E, Herraiz M, Morinigo A, Roca M, Rodriguez A. Risperidona en el tratamiento de los sintomas psicoticos, afectivos y rastornos de la conducta asociados a demencia tipo Alzheimer. Actas Esp Psiquiatr 1999; 27(3): 185-90.
  190. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157(7): 1150-5.
  191. Herrmann N, Rivard MF, Flynn M, Ward C, Rabheru K, Campbell B. Risperidone for the treatment of behavioral disturbances in dementia: a case series. J Neuropsychiatry Clin Neurosci 1998; 10(2): 220-3.
  192. Clark WS, Street JS, Sanger TM, Feldman PD, Breier AF. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer`s dementia. APA Chicago 2000.
  193. Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord 2000; 15(2): 301-4.
  194. Cohen SA, Ihrig K, Lott RS, Kerrick JM. Risperidone for aggression and self-injurious behavior in adults with mental retardation. J Autism Dev Disord 1998; 28(3): 229-33.
  195. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000;15:201-11.
  196. Molho ES, Factor SA. Worsening of motor features of parkinsonism with olanzapine. Mov Disord 1999; 14(6): 1014-6.
  197. Menza MM, Palermo B, Mark M. Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease. Ann Clin Psychiatry 1999; 11(3): 141-4.
  198. Soler Insa PA, Gascón J. Recomendaciones terapéuticas en los trastornos mentales. RTM-II. Comité de consenso de Catalunya en terapéutica de los trastornos mentales. 2ª ed. Masson S.A. 1999.
  199. Buitelaar JK. Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol 2000; 10(1): 19-26.
  200. Cohen SA, Ihrig K, Lott RS, Kerrick Jm. Risperidone for aggression and self-injourious behavior in adults with mental retardation. J Autism Dev Disord 1998; 28: 229-33.
  201. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 2000; 39(4): 509-16.
  202. Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Dev Disord 1997; 27(3): 313-23.

Título español
Resumen
 Palabras clave
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

  English title
  Abstract
  Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia

Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Inicio/Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008